gaxilose
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Oct 1, 2015 (NCT02636413)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
- Beta-galactosidaseSUBSTRATE
GLB1 substrate
Chemistry & pharmacology
Loading structure…
SMILES
O=C[C@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O- Mol. weight
- 312.27 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297512 ↗
Also known as
- 4-o-galactopyranosylxylose
- 4-o-galactosyl-d-xylose
- 4-o-galactosylxylose
- gaxilose
- gaxilose
- gaxilose
- gaxilose
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02636413 | Phase 4 | Oct 1, 2015 | Universidad Complutense de Madrid, VenterPharma |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Universidad Complutense de Madrid | Academic/Hospital | 1 | 0 | 1 | 2015 |
| VenterPharma | For profit | 1 | 1 | 1 | 2015 |
2 organizations
Page 1 / 1